Dmitriy Zamarin, MD, PhD
Immunotherapy is slowly evolving in the gynecologic malignancies landscape and has moved beyond only having a role in ovarian cancer, according to Dmitriy Zamarin, MD, PhD.
on Treatment of Ovarian Cancer, Zamarin, a medical oncologist at Memorial Sloan Kettering Cancer Center, discussed the role of immunotherapy for patients with gynecologic malignancies.
OncLive: Beyond ovarian cancer, in what other gynecologic malignancies has immunotherapy shown potential?
Ovarian cancer is not the only cancer that we treat with immunotherapy. Immunotherapy has also been shown to be effective in endometrial cancer. We already have a very effective drug, pembrolizumab, approved for MSI-H endometrial cancers or for any MSI-H tumor. It could encompass some of the patients with ovarian cancer, but it is specific to the endometrial histology.
Some of the studies will combine adoptive T-cell transfer with immune checkpoint inhibitors which will hopefully make these T cells even more beneficial. There is a lot of room for development, but the studies are ongoing and we are anxiously awaiting these results.
Can you discuss the NIH data regarding the adoptive T-cell therapy?
There was a clinical trial published in the Journal of Clinical Oncology in 2014 or 2015 on the first cohort of patients. They have some updated trials that are currently ongoing.
What is the rationale for exploring lenvatinib in combination with pembrolizumab for patients with endometrial cancer?
That was a multi-cancer type trial. The endometrial cancer data were reported at the 2017 ASCO Annual Meeting. They also presented the data at the 2017 ESMO Congress for the combination of lenvatinib with pembrolizumab with the renal cell carcinoma population, which also demonstrated promising response rates and PFS.
... to read the full story